What is Syantra?
Syantra is pioneering advancements in oncology with its proprietary Onco-ID platform. This technology is designed to detect cancer at earlier stages by analyzing subtle shifts within the human immune system. The company's mission is to enhance treatment efficacy and improve patient outcomes by providing healthcare providers and clinical research partners with novel diagnostic tools. Syantra's commitment to innovation has been recognized through various industry awards, highlighting its potential to transform cancer care.
How much funding has Syantra raised?
Syantra has raised a total of $6.6M across 1 funding round:
Series A
$6.6M
Series A (2024): $6.6M with participation from WealthPoint at CG Wealth Management
Key Investors in Syantra
WealthPoint at CG Wealth Management
WealthPoint at CG Wealth Management is a boutique wealth management firm specializing in holistic financial planning and generational wealth preservation. Their consultative approach focuses on creating customized strategies to help clients achieve their financial goals.
What's next for Syantra?
With this major strategic investment, Syantra is poised for significant expansion and further development of its Onco-ID platform. The Series A financing indicates a transition from early-stage development to a scaling phase, likely focusing on broadening clinical study participation, accelerating commercialization efforts, and enhancing market penetration. The company's strategic focus on leveraging the immune system for early cancer detection positions it for substantial growth in the competitive healthcare technology sector.
See full Syantra company page
